⌘K

Login Start Free

Home/Filings/4/0000897069-24-000925

4//SEC Filing

Young David 4

Accession 0000897069-24-000925

CIK 0001533743other

View on SEC.gov Company Profile

Filed

Apr 11, 8:00 PM ET

Accepted

Apr 12, 5:01 PM ET

Size

10.6 KB

Accession

0000897069-24-000925

Insider Transaction Report

Form 4

Period: 2024-01-01

Processa Pharmaceuticals, Inc.PCSA

DirectorPres. Research & Development

Transactions

Exercise/Conversion
Common Stock
2024-01-01+1,675→ 81,062 total
Tax Payment
Common Stock
2024-01-01$2.79/sh−518$1,445→ 80,544 total
Exercise/Conversion
Restricted Stock Units
2024-01-01−1,675→ 19,333 total
Exercise: $0.00→ Common Stock (1,675 underlying)

Holdings

Common Stock
(indirect: By Family Entities)
10,786
Common Stock
(indirect: By LLC)
18,544
Common Stock
(indirect: By Trust)
30,985

Footnotes (2)

[F1]Distribution of vested restricted shares.
[F2]Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Documents

1 file

4
form4.xmlPrimary

Issuer

Processa Pharmaceuticals, Inc.

CIK 0001533743

Entity typeother

Related Parties

1

filerCIK 0001378166

Filing Metadata

Form type: 4
Filed: Apr 11, 8:00 PM ET
Accepted: Apr 12, 5:01 PM ET
Size: 10.6 KB

View on SEC.gov